CORDIS
EU research results

CORDIS

English EN
Advanced spectroscopic hemogram for personalized care against live threatening infections using an integrated chip-assisted bio-photonic system

Advanced spectroscopic hemogram for personalized care against live threatening infections using an integrated chip-assisted bio-photonic system

Objective

Life threatening infectious diseases and sepsis are worldwide problems with high mortalities. In order to select optimal treatments for the highly heterogeneous group of sepsis patients and to reduce costs, novel multiplexed tools that better characterize the patient and its specific immune response are highly desired.In the novel project "HemoSpec" a multidisciplinary team develops - driven by the demands of the two clinical partners - a highly innovative technological platform for early, fast and reliable medical diagnosis of infectious diseases using only minimal amounts of patient's blood. HemoSpec combines in one device three key enabling technologies: automated microfluidic sample handling with integrated holographic blood count, simultaneous multiplex fluorescence biomarker sensing and detailed Raman spectroscopic leukocyte characterization. In each of the technologies experts in the consortium can build on previous knowledge and will improve system characteristics for higher performance and functionality. Strong focus will be on the miniaturization, optimization as well as on the integration of the individual parts. One common user interface, common data storage and analysis software will make the dense information from HemoSpec available to the clinical enduser in a single working step. The integrated multiplex analysis of HemoSpec will be validated in two clinics in two countries specialized on hospital-acquired and community-acquired sepsis, respectively.Strong industrial participation (four companies from four different countries) spanning the portfolio from biomarker supply to spectrometer companies up to software integrators assures ultimate exploitation of the innovative developments and the final device on the market leading to enhanced European market leadership in the field of medical diagnosis. Ultimately, this can help to administer the right therapy to the right patient at the right time reducing the costs in the health care sector.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.

Address

Albert Einstein Strasse 9
07745 Jena

Germany

Activity type

Research Organisations

EU Contribution

€ 962 072

Administrative Contact

Gabriele Hamm (Ms.)

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

Universitätsklinikum Jena

Germany

EU Contribution

€ 598 568

VIROGATES AS

Denmark

EU Contribution

€ 133 800

HORIBA FRANCE SAS

France

EU Contribution

€ 216 733

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 325 800

DATAMED SRL

Italy

EU Contribution

€ 464 918

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 590 909

BMD SOFTWARE LDA

Portugal

EU Contribution

€ 484 200

Project information

Grant agreement ID: 611682

Status

Closed project

  • Start date

    1 November 2013

  • End date

    31 October 2017

Funded under:

FP7-ICT

  • Overall budget:

    € 5 069 233

  • EU contribution

    € 3 777 000

Coordinated by:

LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.

Germany